TABLE 1.
fT>MIC profiles for ceftazidime at 2 g every 8 h (2-h infusion) as monotherapy and in combination with avibactam at 500 mg (2-h infusion) in mice and humansa
| MIC (mg/liter) | Ceftazidime ƒT>MIC (%) inb: |
||
|---|---|---|---|
| Humans (CAZ-AVI) | Mice (CAZ) | Mice (CAZ-AVI) | |
| 4 | 100 | 100 | 99 |
| 8 | 96 | 87 | 88 |
| 16 | 63 | 58 | 62 |
| 32 | 24 | 28 | 34 |
| 64 | 0 | 0 | 0 |
a
Adapted from reference 9. Ceftazidime ƒT>MIC (%) for CAZ and CAZ-AVI regimens were derived from a previous study in neutropenic mice (9). In that study, target concentrations and exposures were similar between immunocompetent and neutropenic animals (data not shown).
b
CAZ-AVI, ceftazidime-avibactam; CAZ, ceftazidime.